Skip to the line map
Before the Needle

What Are the Risks of Unapproved Stem Cell Injections?

  • Updated November 14, 2026
  • Stop 3 of 4 on the FDA status and safety line

Unapproved stem-cell-labeled injections can cause serious harm, including infections that require hospitalization, and FDA has received reports of blindness and tumor formation linked to unapproved regenerative products. FDA has not approved these products for the specific uses being offered, so FDA has not confirmed that they are safe and effective for those uses; the evidence for safety and effectiveness has to be evaluated for each product and use. The size of the risk depends on what the product actually is, how it was processed and handled, where it is injected, and the person receiving it.

What makes an injection “unapproved”?

FDA approves specific products for specific uses. Three situations are often blurred together and are worth separating. A product with no FDA license at all, sold as treatment, is unapproved. An approved product used for a condition outside its label is “off-label” use: the product itself is approved, but its safety and benefit for that other condition have not been established through FDA review. And an investigational product given inside a registered study under an FDA IND is legally permitted research, not marketed treatment. As of November 14, 2026, no stem cell product in FDA’s directory is approved for joint, tendon or back injections; the approved products and their exact uses are listed in which stem cell therapies are FDA-approved.

Unapproved does not always mean improper. As noted above, an investigational product can be given legally inside a clinical study conducted under an FDA Investigational New Drug application (IND), with informed consent and oversight by an ethics board. FDA also has a separate expanded access pathway for people with a serious or life-threatening condition who have no comparable or satisfactory alternative; each request needs agreement from a physician, an ethics board and the company, and FDA decides whether it may proceed. It is not permission for a clinic to sell an unapproved product to the public. The concern is products marketed and sold as treatment outside these frameworks. FDA’s patient information on regenerative medicine warns that when these products are sold to patients, or offered outside a clinical trial, the offer is likely to be both deceptive and illegal.

What adverse outcomes have regulators documented?

A documented infection cluster. In December 2018, the CDC reported 12 patients in Texas, Florida and Arizona who developed bacterial infections after receiving injections of an umbilical cord blood-derived product processed by Genetech, Inc. and distributed by Liveyon, LLC. The product had been given between February and September 2018, mostly by injection into joints, for conditions including pain, osteoarthritis, rotator cuff tears and rheumatoid arthritis. All 12 patients were hospitalized, for 4 to 58 days; none died. CDC cultured bacteria, including Enterobacter cloacae and Escherichia coli, from unopened vials of the product, and investigators’ initial findings suggested contamination occurred before distribution. The company issued a voluntary recall on September 28, 2018. The report notes the product was not FDA-approved and that FDA registration of a manufacturer is not a form of approval.

Reports received by FDA. FDA states that it has received reports of blindness, tumor formation and infections, including life-threatening blood infections, associated with unapproved regenerative medicine products. In December 2019, it also reported multiple serious adverse events in Nebraska patients who received unapproved products marketed as containing exosomes.

What these reports can and cannot tell you. A case cluster or a set of reports shows that serious harm has happened. It does not give a rate. Nobody knows how many people received these products in total, so the reports cannot be turned into a percentage risk for any one injection, and they should not be read as the rate for every regenerative product.

What risks come from the procedure versus the biological product?

It helps to separate three sources of risk:

Source Examples
The harvest, if your own tissue is collected Pain, bleeding or infection at the bone marrow or fat collection site
The injection Infection, bleeding, injury to nerves or vessels near the needle path, reactions at the site
The product itself Contamination during processing or storage, inflammatory or immune reactions, unintended tissue growth, variable or unknown contents

FDA’s patient page also lists the risk that a person delays or forgoes an effective approved treatment while relying on an unproven one.

Can using your own cells eliminate the risk?

No. Your own cells avoid some immune problems that donor cells can cause, but they do not remove the others. Cells taken out of your body, processed, possibly mixed with other substances, and put back can be contaminated if sterile handling fails. Processing can change how cells behave. And the harvest and injection carry their own procedure risks. FDA’s guidance does not exempt a person’s own cells from these concerns.

Which safety questions matter before a proposed injection?

Use this checklist with the treating clinician. Questions about whether the clinic’s advertised claims are supported by evidence are covered separately in how to check a stem cell clinic’s claims.

Product identification

  • What is the product called, who makes it, and what is its source?
  • Is it FDA-approved for my condition, or given under an IND in a registered study?

Procedure safety

  • Where exactly will the harvest and injection happen, and with what guidance?
  • How is sterility maintained during collection, processing and injection?
  • What complications are known for this injection site?

Informed consent

  • Will I receive written information about the product, its known risks and the evidence behind it?
  • Who oversees the procedure, and is an ethics board involved?

After the injection

  • Which symptoms should prompt me to call, and whom do I call after hours?
  • Where should I go if I need emergency care, and what should I tell them about the product?

How are suspected adverse events reported?

Sudden loss of vision is an emergency; the Merck Manual advises seeing an ophthalmologist or going to an emergency department right away. Suspected sepsis, a life-threatening body-wide response to infection, also needs emergency care. CDC describes sepsis as a medical emergency and lists signs that include confusion or disorientation, shortness of breath, a racing heartbeat or weak pulse, fever, chills or feeling unusually cold, intense pain or distress, and damp or sweaty skin. A person may have only one or a few of these, not all of them. After an injection, new confusion or severe trouble breathing needs emergency care even without a fever, and so does fever or chills that come with confusion, shortness of breath, a racing heartbeat or feeling severely unwell; in the United States, go to an emergency department or call 911. After any injection into or near the eye, pain or vision problems that are getting worse call for contacting an eye doctor right away, because they can be signs of infection, as the National Eye Institute advises; if you cannot reach one promptly, go to an emergency department. Fever or chills on their own, without those warning signs, or worsening pain or swelling at the injection site, still call for medical assessment the same day; if they get worse while you wait, treat them as an emergency. In every case, bring the product name and clinic details. Possible infections after injections can become serious quickly, as the 2018 cluster showed.

Patients and health professionals can report a suspected problem to FDA’s MedWatch program, online, by mail or by fax; FDA’s December 2019 safety alert on unapproved stem cell and exosome products lists the reporting options. FDA also invites questions and complaints about regenerative products at ocod@fda.hhs.gov.

Autologous injections are not automatically safer; they avoid some immune risks but keep the risks of harvest, processing, contamination and injection.

An unapproved treatment is not always part of a clinical trial. Some are given inside registered, IND-overseen studies; others are sold directly to patients outside any study, which is the setting FDA has warned about.

Every stop on the FDA status and safety line

  1. Which Stem Cell Therapies Are FDA-Approved in the United States?
  2. Are Exosome Injections FDA-Approved in the United States?
  3. What Are the Risks of Unapproved Stem Cell Injections?
  4. How to Check Whether a Stem Cell Clinic’s Claims Are Supported by Evidence

Reader comments

Leave a note on this stop

Your email address will not be published. Required fields are marked *